查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1997287

格雷夫茲病市場：2026-2032年全球市場預測（依診斷方法、治療方法、藥物類別、給藥途徑、年齡層、治療階段、最終用戶和分銷管道分類）

Graves Disease Market by Diagnostics, Treatment Type, Drug Class, Route Of Administration, Age Group, Line Of Therapy, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，格雷夫茲病市場價值將達到 6.7855 億美元，到 2026 年將成長至 7.1723 億美元，到 2032 年將達到 10.152 億美元，年複合成長率為 5.92%。

主要市場統計數據
基準年 2025 6.7855億美元
預計年份：2026年 7.1723億美元
預測年份：2032年 1,015,200,000 美元
複合年成長率 (%) 5.92%

簡潔的臨床和策略概述，將格雷夫茲病定位為多領域的醫療保健挑戰，需要整合診斷和個人化治療管道。

格雷夫茲病是一種複雜的自體免疫甲狀腺疾病，其影響範圍遠超內分泌學範疇，遍及全身。臨床上，其特徵是由針對甲狀腺刺激素受體的刺激性抗體引起的甲狀腺功能亢進，但其影響是多方面的，包括心血管健康、眼部功能、代謝狀態和生活品質。準確的診斷和及時的治療性介入對於降低發病率、預防長期併發症以及最佳化不同患者群體的功能預後至關重要。因此，包括診斷實驗室、製藥企業、醫療服務提供者、保險公司和患者權益組織在內的各方利益相關人員日益認知到，需要建立以精準診斷、個別化治療方法選擇和持續隨訪護理為核心的綜合護理路徑。

重建護理路徑和相關人員合作：關於診斷技術進步、治療創新和醫療保健服務體系轉型的思考。

近年來，診斷技術、治療方案和醫療服務模式的進步推動了格雷夫茲病檢測、後續觀察和治療的變革性變化。高靈敏度和高特異性的促甲狀腺激素受體抗體血清學檢測，以及先進的影像學技術，提高了診斷準確性，使臨床醫生能夠更有效地對患者進行分層，並降低診斷的不確定性。同時，治療模式也在不斷發展。儘管抗甲狀腺藥物和放射性碘療法仍是主流，但人們越來越關注標靶免疫調節療法和個人化給藥策略，以減少過度治療和不利事件。這些臨床轉變伴隨著遠端醫療到內分泌疾病後續觀察中、遠端監測甲狀腺功能檢查以及利用數位化工具支援藥物依從性和症狀追蹤。

對 2025 年關稅對醫用同位素、診斷試劑和醫療設備採購的影響進行策略評估，以及為確保臨床連續性而必須進行的營運調整。

2025年的政策和貿易趨勢引入了新的關稅措施，這些措施對與格雷夫斯病治療相關的醫療用品產生了微妙的影響。影響醫用同位素、專用診斷試劑和某些醫療設備進口的關稅調整，增加了醫院和檢查室採購的複雜性。因此，採購團隊在採購促甲狀腺激素受體檢測試劑、用於治療和攝取測試的放射性碘以及超音波和核醫療設備時，必須應對成本結構的變化、供應商合約的更新以及潛在的交貨前置作業時間波動。受這些影響，服務提供者被迫重新審視供應商多元化策略，增加關鍵物品的庫存緩衝，並簽訂長期採購協議，以保護臨床服務免受短期貿易波動的影響。

將診斷方法、治療方法、患者群體、給藥途徑和分銷管道與可操作的臨床和商業性重點聯繫起來的綜合細分分析。

該細分首先從診斷方法入手，並概述了一個分析框架，用於理解格雷夫茲病中不同的臨床管道和商業性動態。基於診斷，市場分析從血液檢查、影像檢查和身體檢查三個角度展開。血液檢查進一步細分為游離4碘甲狀腺素和T3水平、甲狀腺刺激素（TSH）水平以及TSH受體抗體；影像檢查則包括放射性碘攝取試驗和甲狀腺超音波。這些診斷區分至關重要，因為它們會影響臨床決策的關鍵節點。具體而言，它們在區分抗體介導的甲亢與其他病因、確定是否需要影像學檢查以識別病灶以及決定監測強度方面發揮著至關重要的作用。

對影響全球市場診斷方法採用和治療提供的區域醫療保健基礎設施、法規環境和准入趨勢進行分析。

區域趨勢對格雷夫茲病的醫療服務和創新療法的應用有顯著影響，美洲、歐洲、中東和非洲以及亞太地區呈現出不同的模式。在美洲，完善的診斷基礎設施和整合的專家網路促進了先進診斷方法和多學科診療模式的早期應用。然而，都市區/醫療服務不足地區之間仍存在差距，凸顯了系統性努力擴大醫療服務覆蓋範圍和推廣遠距遠端醫療監測的必要性。在歐洲、中東和非洲，不同的法規結構和不平衡的報銷環境影響著新的診斷和治療方法惠及病患的速度。同時，成熟的專科中心往往是最佳實踐通訊協定和合作臨床研究的樞紐。值得注意的是，許多國家醫療體系強調以指南為基礎的醫療服務和以價值為基礎的報銷，這會影響高成本創新療法的應用速度。

企業優先事項的分析著重於診斷技術創新、治療方法差異化、供應鏈穩健性和綜合商業化策略，以實現永續的影響。

格雷夫茲病生態系中的企業策略正朝著幾個共同的優先事項匯聚：提高診斷準確性、最佳化治療的安全性和有效性，以及加強供應鏈和商業化能力。診斷公司正在投資開發用於檢測促甲狀腺激素受體抗體的高靈敏度免疫檢測，以及將血清學檢測結果與影像數據相結合的整合平台，以支持臨床醫生的決策。製藥和生物技術開發公司正在研發差異化的抗甲狀腺藥物、更安全的放射性碘療法給藥方案，以及針對潛在自體免疫機制的生技藥品製劑候選藥物，臨床研究中心和開發公司之間也開展了大量合作，以加速轉化醫學進程。

為了推動臨床和商業性的成功，領導者需要切實可行的策略方法來整合診斷準確性、供應鏈韌性、支付者參與和病患准入模式。

產業領導者必須採取以患者為中心、積極主動的方式，在最大限度地推進臨床進展的同時，降低營運風險。首先，應投資整合診斷生態系統，支援引入高特異性檢測方法和影像工作流程，從而實現精準的患者分層並縮短診斷時間。同時，應優先開發適用於不同年齡層的安全性和耐受性良好的治療策略，並將資源分配給能夠產生療效比較數據和真實世界數據的臨床項目，以支持與支付方的諮詢。其次，應透過供應商多元化、區域製造夥伴關係以及關鍵原料（例如放射性藥物和檢測試劑）的庫存管理措施，增強供應鏈韌性，從而降低貿易中斷和關稅波動帶來的風險。

透明且可重複的混合方法研究框架，結合系統文獻綜述、專家訪談和資料三角驗證，確保臨床和操作有效性。

本研究途徑結合了對第二手資料的嚴格審查和有針對性的原始資料收集，以確保分析的穩健性和臨床有效性。二手資料研究包括對同行評審文獻、臨床指南、監管文件和供應商技術規範進行系統性審查，以建立關於病理學、診斷技術和治療方法的全面知識庫。為了補充這項知識庫，原始數據研究包括對內分泌學家、核子醫學專家、實驗室主管、藥劑師和醫療系統採購經理進行結構化訪談，以了解實際操作情況、未滿足的需求以及推廣應用的障礙。數據三角檢驗確保了研究結果在資訊來源之間得到交叉檢驗，並透過與專家進行後續諮詢和敏感性檢驗來解決差異。

一份簡潔、全面的分析報告，重點介紹了診斷和治療方面的進展，以及供應鏈和政策方面的挑戰，這些挑戰需要採取協調一致的策略行動。

這項分析表明，格雷夫茲病的治療管理正處於一個轉折點，精細的診斷、創新的治療方法和切實可行的營運規劃正在共同塑造未來的治療標準。血清學檢測和成像技術的進步使得早期診斷更加準確，不斷發展的治療方案和護理模式有望提高安全性並改善以患者為中心的治療效果。然而，在這些機會的同時，也存在著系統性挑戰，包括供應鏈脆弱性、與關稅相關的採購複雜性以及部署模式的區域差異，所有這些都需要謹慎的策略性應對。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：格雷夫茲病市場：依診斷方法分類

  • 驗血
    • 甲狀腺刺激素（TSH）水平
    • 游離4碘甲狀腺素和T3濃度
    • TSH受體抗體（TSH-RAb）
  • 影像檢查
    • 甲狀腺超音波檢查
    • 放射性碘攝取試驗
  • 身體檢查

第9章 格雷夫茲病市場：依治療方法

  • 抗甲狀腺藥物
  • 放射性碘療法
  • 手術介入

第10章：格雷夫茲病藥物市場：依藥物類別分類

  • 硫胺類藥物
    • 甲巰咪唑
    • 丙硫氧嘧啶
    • 卡比馬唑
  • BETA阻斷劑
  • 皮質類固醇

第11章：格雷夫茲病市場：依給藥途徑分類

  • 口服
  • 靜脈

第12章：格雷夫茲病市場：依年齡層別分類

  • 兒童
  • 成人
  • 老年人

第13章：格雷夫茲病市場：依治療階段分類

  • 一線治療
  • 二線治療
  • 三線療法

第14章：格雷夫茲病市場：依最終用戶分類

  • 醫院
  • 診所
  • 門診手術中心
  • 診斷實驗室

第15章：格雷夫茲病市場：依通路分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第16章：格雷夫茲病市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第17章：格雷夫茲病市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第18章：格雷夫茲病市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章：美國格雷夫茲病市場

第20章：中國的格雷夫茲病市場

第21章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AdvanceCor GmbH
  • Amgen Inc.
  • Cadila Pharmaceuticals Limited
  • CORONA Remedies Limited
  • Daxia Healthcare Pvt Ltd.
  • Eris Lifesciences Ltd
  • F. Hoffmann-La Roche Ltd.
  • Immunovant, Inc. by Roivant Sciences Ltd.
  • Macleods Pharmaceuticals Ltd.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Salvavidas Pharmaceutical Pvt. Ltd.
  • Siemens Healthineers AG
  • Steris Healthcare Pvt Ltd
  • Sun Pharmaceutical Industries Ltd
  • Synmedic Laboratories by Dhanuka Laboratories Limited
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • Wellona Pharma
Product Code: MRR-42653751EADD

The Graves Disease Market was valued at USD 678.55 million in 2025 and is projected to grow to USD 717.23 million in 2026, with a CAGR of 5.92%, reaching USD 1,015.20 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 678.55 million
Estimated Year [2026] USD 717.23 million
Forecast Year [2032] USD 1,015.20 million
CAGR (%) 5.92%

A concise clinical and strategic overview that frames Graves disease as a multidisciplinary healthcare challenge demanding integrated diagnostics and tailored therapeutic pathways

Graves disease represents a complex autoimmune thyroid disorder with systemic implications that extend far beyond endocrinology clinics. Clinically, it is characterized by hyperthyroidism driven by stimulating antibodies against the thyroid-stimulating hormone receptor, but its impact is multidisciplinary-affecting cardiovascular health, ophthalmic function, metabolic status, and patient quality of life. Accurate diagnosis and timely therapeutic intervention are essential to reduce morbidity, prevent long-term complications, and optimize functional outcomes for diverse patient populations. Consequently, stakeholders across diagnostic labs, pharmaceutical manufacturers, providers, payers, and patient advocacy groups increasingly recognize the need for integrated care pathways that emphasize precision diagnostics, individualized treatment selection, and continuity of follow-up care.

Against this clinical backdrop, the landscape is evolving rapidly: improvements in immunoassays, imaging techniques, and digital health platforms are reshaping diagnostic workflows; therapeutic innovation including targeted biologics and refined radioiodine protocols is altering treatment algorithms; and payers are recalibrating coverage frameworks to reflect outcomes-based priorities. Given this multifaceted shift, leaders must synthesize clinical evidence, regulatory developments, and operational realities to adapt strategies that prioritize patient-centric outcomes while maintaining fiscal responsibility. This introduction frames the subsequent analysis by highlighting both the persistent clinical challenges and the opportunities for transformative improvement across care delivery, diagnostics, and therapeutic innovation.

An exploration of diagnostic advances, therapeutic innovation, and healthcare delivery transformation reshaping care pathways and stakeholder collaborations

The last several years have seen transformative shifts in how Graves disease is detected, monitored, and treated, driven by advances in diagnostics, therapeutic options, and healthcare delivery models. Diagnostic precision has improved through more sensitive and specific serological assays for TSH receptor antibodies and refined imaging modalities, enabling clinicians to stratify patients more effectively and reduce diagnostic uncertainty. Simultaneously, therapeutic paradigms are evolving: while antithyroid medications and radioiodine therapy remain mainstays, there is accelerating interest in targeted immunomodulatory approaches and personalized dosing strategies that reduce overtreatment and adverse events. These clinical changes are accompanied by broader system-level shifts, including the integration of telemedicine into endocrine follow-up, remote monitoring of thyroid function tests, and digital tools that support medication adherence and symptom tracking.

In parallel, regulatory and reimbursement environments are adapting to evidence demonstrating value in targeted diagnostics and therapies, prompting earlier adoption of precision tools in specialist centers and select health systems. Supply chain resilience and localized manufacturing capacity have also risen in importance, as stakeholders aim to secure critical inputs such as radiopharmaceuticals and assay reagents. Collectively, these shifts are driving a more nuanced ecosystem in which clinicians, diagnostics developers, and therapeutic innovators collaborate to deliver patient-centered care pathways that are evidence-informed, scalable, and sustainable.

A strategic assessment of 2025 tariff effects on medical isotope, diagnostic reagent, and device procurement and the operational adjustments required to protect clinical continuity

Policy and trade developments in 2025 introduced new tariff measures that have nuanced implications for medical inputs relevant to Graves disease care. Tariff adjustments affecting imports of medical isotopes, specialized diagnostic reagents, and certain medical devices have raised procurement complexity for hospitals and laboratories. As a result, purchasing teams must navigate altered cost structures, updated supplier contracts, and potential lead-time variability when acquiring reagents for TSH receptor assays, radioactive iodine supplies for therapy and uptake studies, and ultrasound and nuclear medicine equipment. These operational impacts have prompted service providers to reassess vendor diversification, increase inventory buffers for critical items, and pursue longer-term purchasing agreements to insulate clinical services from short-term trade fluctuations.

Moreover, tariff-driven procurement shifts are accelerating consideration of domestic production options and regional supplier networks to reduce exposure to cross-border uncertainties. Health systems and diagnostic labs are increasingly evaluating local contract manufacturing and collaborative supply arrangements to maintain continuity of care. Importantly, regulators and payers are mindful of access implications; where tariffs raise the cost of delivering specific diagnostic tests or therapies, stakeholders may need to work with payers to adjust reimbursement policies or explore alternative care models that preserve clinical outcomes while containing costs. Transitioning through these challenges requires cross-functional planning, proactive stakeholder engagement, and scenario-based operational playbooks to ensure patient access is maintained while organizations adapt to evolving trade realities.

An integrative segmentation analysis linking diagnostic modalities, therapeutic approaches, patient cohorts, delivery routes, and distribution channels to actionable clinical and commercial priorities

Segmentation provides the analytical scaffolding to understand heterogeneous clinical pathways and commercial dynamics in Graves disease, beginning with diagnostic modalities. Based on diagnosis, the market is examined across blood tests, imaging tests, and physical examination; blood tests are further delineated into Free T4 and T3 levels, thyroid-stimulating hormone (TSH) levels, and TSH receptor antibodies, while imaging tests include radioactive iodine uptake studies and thyroid ultrasound. These diagnostic distinctions matter because they drive clinical decision points-differentiating antibody-mediated hyperthyroidism from other etiologies, defining the need for imaging-based localization, and informing the intensity of monitoring.

From a treatment perspective, segmentation by treatment type distinguishes antithyroid medications, beta-blockers, and radioactive iodine therapy, reflecting different efficacy, safety, and monitoring requirements that influence procurement, reimbursement, and patient education programs. Age group segmentation across adult, elderly, and pediatric cohorts highlights variability in presentation, comorbidity burden, and treatment tolerability, which in turn affects clinical guidelines and therapeutic prioritization. Segmentation by route of administration-intravenous versus oral-captures differences in care setting, administration infrastructure, and adherence considerations. Finally, distribution channel segmentation across hospital pharmacies, online pharmacies, and retail pharmacies influences access, dispensing workflows, and patient support services. Taken together, these segmentation lenses enable tailored strategies for diagnostics developers, therapeutics manufacturers, and healthcare providers by clarifying where clinical needs, delivery mechanisms, and commercial opportunities intersect.

A region-by-region examination of healthcare infrastructure, regulatory environments, and access dynamics shaping diagnostic adoption and therapeutic delivery across global markets

Regional dynamics exert profound influence on care delivery and innovation adoption for Graves disease, with distinct patterns emerging across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, robust diagnostic infrastructure and integrated specialist networks facilitate early adoption of advanced assays and multidisciplinary clinics; yet disparities persist between urban centers and rural or underserved communities, prompting system-level initiatives to expand access and telehealth-enabled monitoring. In Europe, Middle East & Africa, varied regulatory frameworks and heterogeneous reimbursement environments shape the pace at which new diagnostics and therapies reach patients, while established specialty centers often serve as hubs for best-practice protocols and clinical research collaborations. Importantly, national health systems in many countries emphasize guideline-driven care and value-based reimbursement, affecting adoption curves for higher-cost innovations.

Across Asia-Pacific, rapid investment in healthcare infrastructure, increasing diagnostic capacity, and expanding clinical research activity are accelerating uptake of novel diagnostics and therapeutic options, although supply chain concentration and regional manufacturing constraints can affect availability of radiopharmaceuticals and specialized reagents. Throughout all regions, differences in prevalence, population age structures, and access to endocrinology specialists demand context-specific strategies: public health programs and provider education campaigns in some markets, targeted reimbursement engagement in others, and operational investments in supply chain resilience where cross-border dependencies are pronounced. These regional insights highlight the need for geographically attuned approaches that balance clinical priorities with system capabilities and policy realities.

An analysis of corporate priorities emphasizing diagnostic innovation, therapeutic differentiation, supply chain robustness, and integrated commercialization strategies for sustained impact

Company strategies in the Graves disease ecosystem are converging on several consistent priorities: advancing diagnostic precision, optimizing therapeutic safety and efficacy, and strengthening supply chain and commercialization capabilities. Diagnostic firms are investing in higher-sensitivity immunoassays for TSH receptor antibodies and in integrated platforms that link serology results with imaging data to support clinician decision-making. Pharmaceutical and biotech developers are pursuing differentiated antithyroid agents, safer dosing regimens for radioiodine therapy, and biologic candidates that target underlying autoimmune mechanisms, with many partnerships forming between clinical research centers and developers to accelerate translational pathways.

Commercially, companies focus on expanding access through diversified distribution strategies that include hospital pharmacy partnerships, specialty distribution contracts, and digital dispensing channels. Manufacturing scale-up and quality-of-supply initiatives address the unique demands of radiopharmaceuticals and reagent production, while strategic collaborations with diagnostic labs and health systems enable real-world evidence collection to support reimbursement dossiers. Additionally, companies are investing in patient support and adherence programs that reduce treatment discontinuation and improve clinical outcomes. Taken together, these corporate priorities underscore a shift toward integrated solutions that combine diagnostics, therapeutics, and services to deliver measurable improvements in patient care.

Practical strategic initiatives for leaders to integrate diagnostic precision, supply chain resilience, payer engagement, and patient access models to drive clinical and commercial success

Industry leaders must adopt a proactive, patient-centered approach to capitalize on clinical advances while mitigating operational risks. First, invest in diagnostic ecosystem integration by supporting the adoption of high-specificity assays and imaging workflows that enable precise patient stratification and reduce diagnostic delay. Coupled with that, prioritize development of therapeutic strategies that emphasize safety and tolerability for diverse age cohorts, while allocating resources toward clinical programs that generate comparative effectiveness and real-world evidence to support payer discussions. Second, fortify supply chain resilience through supplier diversification, regional manufacturing partnerships, and inventory management practices for critical inputs such as radiopharmaceuticals and assay reagents, thereby reducing vulnerability to trade disruptions and tariff volatility.

Third, expand patient access via hybrid distribution and care models that blend hospital-based services with telehealth-enabled follow-up and pharmacy-based medication delivery. This includes partnering with pharmacies and digital health platforms to improve adherence and monitoring. Fourth, engage early and transparently with regulators and payers to align clinical development with evidentiary requirements and to explore value-based contracting where appropriate. Finally, invest in workforce training across endocrinology, nuclear medicine, and primary care to ensure guideline-concordant management and to accelerate uptake of emerging diagnostics and therapies. Implementing these recommendations will help organizations balance innovation adoption with operational sustainability and improved patient outcomes.

A transparent and reproducible mixed-methods research framework combining systematic literature review, expert interviews, and data triangulation to ensure clinical and operational validity

The research approach combines rigorous secondary evidence review with targeted primary data collection to ensure analytical robustness and clinical relevance. Secondary research entailed systematic review of peer-reviewed literature, clinical guidelines, regulatory documents, and vendor technical specifications to establish a comprehensive knowledge base on pathophysiology, diagnostic technologies, and therapeutic modalities. Primary research complemented this foundation through structured interviews with endocrinologists, nuclear medicine specialists, laboratory directors, pharmacists, and health system procurement leaders to capture frontline operational realities, unmet needs, and adoption barriers. Data triangulation ensured findings were cross-validated across sources, with discrepancies resolved through follow-up expert consultations and sensitivity checks.

Methodological safeguards included explicit inclusion and exclusion criteria for clinical studies and product assessments, transparent documentation of interview protocols and respondent roles, and qualitative coding of expert insights to identify recurrent themes. Geographic coverage targeted a balanced representation of markets to reflect variation in healthcare delivery and regulatory contexts. The study also acknowledges limitations, including the evolving nature of clinical evidence and potential variability in regional data availability, and recommends periodic updates and targeted primary studies for high-priority subtopics. Overall, the methodology emphasizes reproducibility, peer validation, and practical relevance for stakeholders involved in Graves disease care and commercial strategy.

A concise synthesis highlighting diagnostic and therapeutic progress alongside supply chain and policy challenges that require coordinated strategic action

This analysis underscores that Graves disease management is at an inflection point where diagnostic refinement, therapeutic innovation, and pragmatic operational planning converge to shape future standards of care. Improvements in serological assays and imaging techniques are enabling earlier, more accurate diagnosis, while evolving therapeutic options and care models offer the prospect of improved safety and patient-centered outcomes. However, these opportunities coexist with systemic challenges including supply chain vulnerabilities, tariff-related procurement complexities, and heterogeneous regional adoption patterns that require deliberate strategic responses.

In summary, stakeholders who align clinical development with real-world operational constraints, invest in resilient supply and distribution networks, and proactively engage payers and regulators will be best positioned to translate scientific advances into tangible patient benefits. Emphasizing integrated care pathways, evidence generation, and scalable delivery models will accelerate the adoption of innovations that improve quality of life for patients living with Graves disease while maintaining sustainable organizational performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Graves Disease Market, by Diagnostics

  • 8.1. Blood Tests
    • 8.1.1. Thyroid-stimulating Hormone (TSH) Levels
    • 8.1.2. Free T4 & T3 Levels
    • 8.1.3. TSH Receptor Antibodies (TSH-RAb)
  • 8.2. Imaging Tests
    • 8.2.1. Thyroid Ultrasound
    • 8.2.2. Radioactive Iodine Uptake
  • 8.3. Physical Examination

9. Graves Disease Market, by Treatment Type

  • 9.1. Antithyroid Medications
  • 9.2. Radioactive Iodine Therapy
  • 9.3. Surgical Interventions

10. Graves Disease Market, by Drug Class

  • 10.1. Thionamides
    • 10.1.1. Methimazole
    • 10.1.2. Propylthiouracil
    • 10.1.3. Carbimazole
  • 10.2. Beta Blockers
  • 10.3. Corticosteroids

11. Graves Disease Market, by Route Of Administration

  • 11.1. Oral
  • 11.2. Intravenous

12. Graves Disease Market, by Age Group

  • 12.1. Pediatric
  • 12.2. Adult
  • 12.3. Geriatric

13. Graves Disease Market, by Line Of Therapy

  • 13.1. First Line Therapy
  • 13.2. Second Line Therapy
  • 13.3. Third Line Therapy

14. Graves Disease Market, by End User

  • 14.1. Hospitals
  • 14.2. Clinics
  • 14.3. Ambulatory Surgical Centers
  • 14.4. Diagnostic Laboratories

15. Graves Disease Market, by Distribution Channel

  • 15.1. Hospital Pharmacies
  • 15.2. Retail Pharmacies
  • 15.3. Online Pharmacies

16. Graves Disease Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Graves Disease Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Graves Disease Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States Graves Disease Market

20. China Graves Disease Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. Abbott Laboratories
  • 21.6. AdvanceCor GmbH
  • 21.7. Amgen Inc.
  • 21.8. Cadila Pharmaceuticals Limited
  • 21.9. CORONA Remedies Limited
  • 21.10. Daxia Healthcare Pvt Ltd.
  • 21.11. Eris Lifesciences Ltd
  • 21.12. F. Hoffmann-La Roche Ltd.
  • 21.13. Immunovant, Inc. by Roivant Sciences Ltd.
  • 21.14. Macleods Pharmaceuticals Ltd.
  • 21.15. Merck KGaA
  • 21.16. Novartis AG
  • 21.17. Pfizer Inc.
  • 21.18. Salvavidas Pharmaceutical Pvt. Ltd.
  • 21.19. Siemens Healthineers AG
  • 21.20. Steris Healthcare Pvt Ltd
  • 21.21. Sun Pharmaceutical Industries Ltd
  • 21.22. Synmedic Laboratories by Dhanuka Laboratories Limited
  • 21.23. Teva Pharmaceutical Industries Ltd.
  • 21.24. Thermo Fisher Scientific Inc.
  • 21.25. Wellona Pharma

LIST OF FIGURES

  • FIGURE 1. GLOBAL GRAVES DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GRAVES DISEASE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GRAVES DISEASE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GRAVES DISEASE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GRAVES DISEASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL GRAVES DISEASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES GRAVES DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA GRAVES DISEASE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GRAVES DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID-STIMULATING HORMONE (TSH) LEVELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID-STIMULATING HORMONE (TSH) LEVELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID-STIMULATING HORMONE (TSH) LEVELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GRAVES DISEASE MARKET SIZE, BY FREE T4 & T3 LEVELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GRAVES DISEASE MARKET SIZE, BY FREE T4 & T3 LEVELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GRAVES DISEASE MARKET SIZE, BY FREE T4 & T3 LEVELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GRAVES DISEASE MARKET SIZE, BY TSH RECEPTOR ANTIBODIES (TSH-RAB), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GRAVES DISEASE MARKET SIZE, BY TSH RECEPTOR ANTIBODIES (TSH-RAB), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GRAVES DISEASE MARKET SIZE, BY TSH RECEPTOR ANTIBODIES (TSH-RAB), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GRAVES DISEASE MARKET SIZE, BY PHYSICAL EXAMINATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GRAVES DISEASE MARKET SIZE, BY PHYSICAL EXAMINATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GRAVES DISEASE MARKET SIZE, BY PHYSICAL EXAMINATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GRAVES DISEASE MARKET SIZE, BY ANTITHYROID MEDICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GRAVES DISEASE MARKET SIZE, BY ANTITHYROID MEDICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GRAVES DISEASE MARKET SIZE, BY ANTITHYROID MEDICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GRAVES DISEASE MARKET SIZE, BY SURGICAL INTERVENTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GRAVES DISEASE MARKET SIZE, BY SURGICAL INTERVENTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GRAVES DISEASE MARKET SIZE, BY SURGICAL INTERVENTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GRAVES DISEASE MARKET SIZE, BY METHIMAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GRAVES DISEASE MARKET SIZE, BY METHIMAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GRAVES DISEASE MARKET SIZE, BY METHIMAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GRAVES DISEASE MARKET SIZE, BY PROPYLTHIOURACIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GRAVES DISEASE MARKET SIZE, BY PROPYLTHIOURACIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GRAVES DISEASE MARKET SIZE, BY PROPYLTHIOURACIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GRAVES DISEASE MARKET SIZE, BY CARBIMAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GRAVES DISEASE MARKET SIZE, BY CARBIMAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GRAVES DISEASE MARKET SIZE, BY CARBIMAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GRAVES DISEASE MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GRAVES DISEASE MARKET SIZE, BY BETA BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GRAVES DISEASE MARKET SIZE, BY BETA BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GRAVES DISEASE MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GRAVES DISEASE MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GRAVES DISEASE MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GRAVES DISEASE MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GRAVES DISEASE MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GRAVES DISEASE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GRAVES DISEASE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GRAVES DISEASE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GRAVES DISEASE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GRAVES DISEASE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GRAVES DISEASE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GRAVES DISEASE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GRAVES DISEASE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GRAVES DISEASE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GRAVES DISEASE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GRAVES DISEASE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GRAVES DISEASE MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GRAVES DISEASE MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GRAVES DISEASE MARKET SIZE, BY FIRST LINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GRAVES DISEASE MARKET SIZE, BY FIRST LINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GRAVES DISEASE MARKET SIZE, BY FIRST LINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GRAVES DISEASE MARKET SIZE, BY SECOND LINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GRAVES DISEASE MARKET SIZE, BY SECOND LINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GRAVES DISEASE MARKET SIZE, BY SECOND LINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GRAVES DISEASE MARKET SIZE, BY THIRD LINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GRAVES DISEASE MARKET SIZE, BY THIRD LINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GRAVES DISEASE MARKET SIZE, BY THIRD LINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GRAVES DISEASE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GRAVES DISEASE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GRAVES DISEASE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GRAVES DISEASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GRAVES DISEASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GRAVES DISEASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GRAVES DISEASE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GRAVES DISEASE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GRAVES DISEASE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GRAVES DISEASE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GRAVES DISEASE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GRAVES DISEASE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GRAVES DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS GRAVES DISEASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL GRAVES DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. GCC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. GCC GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 221. GCC GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
  • TABLE 222. GCC GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 223. GCC GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. GCC GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. GCC GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 226. GCC GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. GCC GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. GCC GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. GCC GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. GCC GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. G7 GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. G7 GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 257. G7 GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
  • TABLE 258. G7 GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 259. G7 GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. G7 GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 261. G7 GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 262. G7 GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. G7 GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. G7 GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 265. G7 GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. G7 GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. NATO GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. NATO GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 269. NATO GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
  • TABLE 270. NATO GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 271. NATO GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. NATO GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 273. NATO GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 274. NATO GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 275. NATO GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 276. NATO GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 277. NATO GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. NATO GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. GLOBAL GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES GRAVES DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA GRAVES DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA GRAVES DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA GRAVES DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA GRAVES DISEASE MARKET SIZE, BY THIONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA GRAVES DISEASE MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)